New York, NY. November 21, 2023 – This year’s Lupus Research Alliance (LRA) Breaking Through Gala raised $2 million for lupus research and brought the hope of tremendous progress that’s improving lupus treatment while driving to a cure. The annual celebration began with a powerhouse performance and moving tribute to lupus warriors by multi-talented pianist, […] READ MORE
This information is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by, nor a part of, the American College of Rheumatology. 30+ presentations of studies funded by the LRA spanning a broad spectrum of research areas Positive results from Phase 2/3 clinical studies supported by LRA affiliate Lupus Therapeutics point to […] READ MORE
NEW YORK, NY. Oct. 26. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to share that the successful results of the Patient Advocates for Lupus Studies (PALS) pilot study were recently published in ACR Open Rheumatology , the official open-access journal of the American College of Rheumatology. The PALS (Patient Advocates […] READ MORE
NEW YORK, N.Y., Oct. 24 – Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ®) in individuals living with systemic lupus erythematosus (SLE). In this partnership, Lupus Therapeutics will assist with study participant recruitment, site activation and engagement […] READ MORE
NEW YORK, Oct. 20, 2023 — Thousands of supporters will join together Saturday, October 21 at the Intrepid Museum (formerly called the Intrepid Sea, Air and Space Museum) to celebrate the 20th Anniversary of the Lupus Research Alliance (LRA) 2023 New York City Walk with Us to Cure Lupus. Registration remains open through Walk Day at www.lupuswalknyc.org. While the well-attended annual event is […] READ MORE
NEW YORK, N.Y. — October 17, 2023: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory […] READ MORE
NEW YORK, NY. August 2. The Lupus Research Alliance (LRA) is pleased to announce that the 2023 Global Team Science Award (GTSA) has been granted to an exceptional multidisciplinary research team of experts in immunology, pediatric rheumatology and nephrology, genetics, and data analysis to identify drivers of lupus nephritis in children with the aim of […] READ MORE
SUMMIT, N.J., July 17, 2023 /PRNewswire/ — Former Super Bowl Champion and Mad Dog Sports radio personality Willie Colon is hosting today the 9th Annual Willie Colon Golf Outing crafted by Tito’s Handmade Vodka for the Lupus Research Alliance (LRA). The event drives lupus awareness and tees up the opening of the Fall season of the grassroots […] READ MORE
NEW YORK, NY. July 12. The Lupus Research Alliance is pleased to announce the 2023 recipients of the Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research. The Diversity in Lupus Research Awards aim to foster the development of outstanding, underrepresented minority scientists and establish a diverse community of researchers and clinicians in […] READ MORE
New York, NY. June 29. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced the launch of three pilot research initiatives for Project CHANGE, a community-driven approach to address systemic challenges contributing to the underrepresentation of people of color, particularly Black people, in lupus clinical trials. The sites selected to participate […] READ MORE
NEW YORK, NY – June 22, 2023 – The Lupus Research Alliance awarded its 2023 Lupus Insight Prize to Carola Vinuesa, MD, PhD, of The Francis Crick Institute, for her seminal discovery that a mutation in a specific human gene causes systemic lupus erythematosus (SLE), uncovering an important target for the development of novel treatment. […] READ MORE
NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through […] READ MORE
